-
Mashup Score: 3
Johnson & Johnson has submitted a type II variation application to the EMA seeking the approval of ibrutinib plus R-CHOP in ASCT-eligible frontline MCL.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3
Johnson & Johnson has submitted a type II variation application to the EMA seeking the approval of ibrutinib plus R-CHOP in ASCT-eligible frontline MCL.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 3
Johnson & Johnson has submitted a type II variation application to the EMA seeking the approval of ibrutinib plus R-CHOP in ASCT-eligible frontline MCL.
Source: www.onclive.comCategories: General Medicine News, Oncologists1Tweet
Johnson & Johnson Seeks EMA Approval for Ibrutinib Plus R-CHOP in Frontline MCL @EMA_News #lymsm #oncology #MedEd #MedTwitter https://t.co/a5GWtYDzov